E2F1 and neuroblastoma: Moreover, pediatric neuroblastoma patients with age at diagnosis < 18 months and with lower E2F1 expression levels had the best clinical event free survival and overall survival than other sub-groups in TARGET, GSE16476, GSE85047 and E-MTAB-1781 datasets (Fig. 5b and supplementary Fig. 2b).